Trial Profile
First-in-human, placebo-controlled, single- and multiple-ascending dose study of GS 4997 in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Apr 2020
Price :
$35
*
At a glance
- Drugs Selonsertib (Primary)
- Indications Alcoholic hepatitis; Diabetic nephropathies; Kidney disorders; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Pulmonary arterial hypertension
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Gilead Sciences
- 25 Apr 2020 Results published in the Clinical Pharmacokinetics
- 25 Nov 2015 New trial record